Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889972 | 1.00 | KIF11 (0.53) | KIF11DAOCYP11B1CYP11B2KDM1A | |
| Bromide SCHEMBL28322451 | 0.98 | KIF11 (0.51) | KIF11DAOCYP11B1CYP11B2KDM1A | |
| SCHEMBL5438861 | 0.84 | DAO (0.51) | KIF11DAOCYP11B1CYP11B2KDM1A | |
| SCHEMBL29766263 | 0.83 | PTPN7 (0.48) | KIF11P2RX7 | |
| SCHEMBL118433 | 0.83 | PTPN7 (0.48) | KIF11P2RX7 | |
| SCHEMBL1775215 | 0.83 | RXRA (0.44) | KIF11DAO | |
| SCHEMBL13208381 | 0.82 | KIF11 (0.36) | KIF11DAO | |
| SCHEMBL78974 | 0.81 | DAO (0.49) | KIF11DAOCYP11B1CYP11B2KDM1A | |
| Bromide SCHEMBL582107 | 0.79 | KIF11 (0.53) | KIF11DAOCYP11B1CYP11B2KDM1A | |
| SCHEMBL12706035 | 0.79 | KIF11 (0.53) | KIF11DAOCYP11B1CYP11B2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640106-B | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2024-03-08 | — | — | CN | claimed |
| CN-116640106-A | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2023-08-25 | — | — | CN | claimed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| CN-118164914-A | Indazole compound and synthetic method and application thereof | 华东师范大学 | 2024-06-11 | — | — | CN | disclosed |
| US-20040142821-A1 | Pesticide composition comprising malononitrile compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1385377-A1 | PESTICIDE COMPOSITION COMPRISING MALONONITRILE COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002089579-A1 | PESTICIDE COMPOSITION COMPRISING MALONONITRILE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-14 | — | — | WO | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | KIF11 3285/4885DAO 519/4885CYP11B1 4648/4885 |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | KIF11 4205/4885DAO 4086/4885CYP11B1 268/4885 |
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | KIF11 4335/4885DAO 865/4885CYP11B1 106/4885 |
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD4, TEAD1, TEAD2 | KIF11 1158/4885DAO 4720/4885CYP11B1 877/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | KIF11 4205/4885DAO 4086/4885CYP11B1 268/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | KIF11 269/4885DAO 3139/4885CYP11B1 1729/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | KIF11 3309/4885DAO 3004/4885CYP11B1 94/4885 |
| US-20040142821-A1 | Pesticide composition comprising malononitrile compounds | CBR1, CBR3, ME1 | KIF11 2829/4885DAO 1631/4885CYP11B1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.